People who live with an immune-mediated disease are suffering from it all their lives. These diseases make the body fight against itself, which can lead to a life of pain and discomfort. Although current treatments have already made a big difference in the lives of many people affected, there remains a great need for medicines that work better, faster, and longer. From our expertise in immunology, we will therefore, continue to work on innovative medicines for immune-mediated diseases such as psoriasis, psoriatic arthritis, and inflammatory bowel disease (IBD).
Psoriasis is one of the most common skin diseases in the world, affecting between 1% and 11.4% of the world's population1. Yet few people know what kind of disease psoriasis is. In psoriasis, the immune system is overactive. The patient's natural defence mechanism works too hard, causing the body to produce new skin cells too quickly. Normally skin cells are renewed approximately every 28 days, but in people with psoriasis this happens every 4 to 6 days2. Skin cells accumulate, resulting in flakes, redness, and itching.
Living with psoriasis
The complaints that cause psoriasis have a negative effect on the patient's daily life. People with psoriasis sleep worse and feel less free to use public facilities or practice sports. More than half of the patients report that they suffer from stress and anxiety3. Psoriasis is relatively often associated with other conditions. For example, people living with psoriasis are more likely to suffer from Crohn's disease, depression and metabolic syndrome (a metabolic disorder associated with, among others, hypertension and diabetes) 4,5,6.
Due to the visible symptoms of psoriasis, the skin disease often goes hand in hand with misunderstanding. For example, many people think that psoriasis is a contagious disease or that it is caused by a lack of hygiene. Of course, this is not true, but this kind of thinking has a major impact on patients' lives. Dutch research has shown that 50% of people exhibit discriminatory behaviour towards psoriasis patients. In addition, 44% of the interviewees said they did not want to start a sexual relationship with someone with psoriasis. Nearly one in three respondents said they did not want to give a hand or kiss on the cheek to people with psoriasis and 7% did not want to get to know someone with psoriasis at all7.
Janssen's commitment to psoriasis
It is not known what causes psoriasis. Psoriasis is a chronic skin condition, which unfortunately cannot yet be cured. Fortunately, there are treatments that reduce the symptoms. But that's not all: the current, available therapies do not always work and/or have too many side effects. Janssen has played a leading role in the search for new treatments over the past decade. We continue to work towards a future in which psoriasis belongs to the past.
By creating a better understanding of psoriasis, we try to change patients' lives. On the occasion of World Psoriasis Day, Janssen launched the new magazine APSOLUTELY. The goal: to increase awareness of psoriasis. The magazine is full of interviews and stories.
More information about Janssen
Read more about our activity in the field of immunology, such as rheumatism and inflammatory bowel disease (IBD), and our other areas of expertise. You can also learn more about Janssen's activities in Belgium and what working at Janssen looks like. You can also follow us via social media on Twitter, Facebook, and LinkedIn to stay up to date with current developments.
Facts & Figures
300,000 Belgians live with psoriasis8.
Psoriasis is not a contagious skin disease and has nothing to do with hygiene.
Depression often occurs together with psoriasis4,5,6.
There are three forms of treatment8:
1. Light therapy
2. Systemic therapy
3. Topical therapy
2Parrish, Liz. "Psoriasis: symptoms, treatments and its impact on quality of life." British Journal of Community Nursing 17.11 (2012): 524-528.
3 Summary of Living with PSO and Plaque Psoriasis: Biologic Patient Experience The Netherlands
4 Shah, Kamal, et al. "Real-world burden of comorbidities in US patients with psoriasis." Journal of the American Academy of Dermatology 77.2 (2017): 287-292.
5Kimball, Alexa B., et al. "National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening." Journal of the American Academy of Dermatology 58.6 (2008): 1031-1042.
6 Aurangabadkar, Sanjeev J. "Comorbidities in psoriasis." Indian Journal of Dermatology, Venereology, and Leprology 79.7 (2013): 10.
7 Omarm Psoriasis (https://www.omarmpsoriasis.nl/)
EM-35405 – 12-jun-2020